Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Invivyd, Inc.ADGI · Entity 721 | See Explanation of Responses | March 28, 2022 | April 06, 2022 |
| MEDICINES CO /DEMDCO · Entity 152552 | EVP & Chief Corp. Dev. Officer | March 04, 2019 | March 06, 2019 |
| Population Health Investment Co., Inc.PHIC · Entity 136038 | Senior Vice President | November 17, 2020 | November 17, 2020 |
| SCIENTIFIC INDUSTRIES INCSCND · Entity 8003 | Director | July 01, 2024 | August 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Invivyd, Inc.
Report date March 28, 2022 · Filed April 06, 2022 · Amendment
Jointly reported with Population Health Equity Partners VII, L.P., Population Health Equity Partners III GP, LLC, Population Health Equity Partners III, L.P., Population Health Equity Partners VII GP, LLC
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 679,822 |
Reported balance
Holding disclosure · report date 2022-03-28 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 679,822 F1: This Form 3 is not being filed in connection with the acquisition or disposition of any securities of the Issuer. F2: 359,662 shares of Common Stock are held directly by Population Health Equity Partners III, L.P. ("PH III") and a further 320,160 shares of Common Stock are held directly by Population Health Equity Partners VII, L.P. ("PH VII"). PH III is controlled by Population Health Equity Partners III GP, LLC ("PH III GP"), its general partner, and PH VII is controlled by Population Health Equity Partners VII GP, LLC ("PH VII GP"), its general partner. Clive Meanwell and Christopher Cox are the sole managing members of both PH III GP and PH VII GP and may be deemed to have shared voting and dispositive power with respect to the shares of Common Stock held directly by PH III and PH VII. Clive Meanwell and Christopher Cox disclaim beneficial ownership of the shares held directly by PH III and PH VII, except to the extent of their pecuniary interests therein, if any. Clive Meanwell has filed a separate Form 3 in respect of the Issuer. F3: On March 28, 2022, PH III, PH VII and Clive Meanwell ("PH") and (i) Mithril II LP ("Mithril"), (ii) M28 Capital Management LP (together with certain of its affiliates, "M28"), (iii) Polaris Venture Partners V, L.P. and certain affiliates (collectively, "Polaris") and (iv) Adimab, LLC, orally agreed to coordinate and cooperate in certain of their activities with regard to the Issuer, which agreement was subsequently memorialized, also on March 28, 2022, in an email circulated among representatives of such persons. That agreement provides that each such person will vote its shares of Common Stock in favor of the election of certain director nominees at the Issuer's 2022 annual meeting. By virtue of such agreement, the forgoing persons may be deemed to be part of a "group" (within the meaning of Section 13(d)(3) of the Exchange Act) comprised of such persons. F4: The Reporting Persons expressly disclaim beneficial ownership over any Common Stock that they may be deemed to beneficially own solely by reason of the agreement reached among Population Health, Mithril, M28, Polaris and Adimab, LLC, and beneficial ownership of any securities of the Issuer other than those reported on this Form 3 in which they have a direct pecuniary interest. This filing shall not be deemed an admission that the Reporting Persons are 10% shareholders for purposes of Section 16 of the Exchange Act. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 3 is not being filed in connection with the acquisition or disposition of any securities of the Issuer.
F2: 359,662 shares of Common Stock are held directly by Population Health Equity Partners III, L.P. ("PH III") and a further 320,160 shares of Common Stock are held directly by Population Health Equity Partners VII, L.P. ("PH VII"). PH III is controlled by Population Health Equity Partners III GP, LLC ("PH III GP"), its general partner, and PH VII is controlled by Population Health Equity Partners VII GP, LLC ("PH VII GP"), its general partner. Clive Meanwell and Christopher Cox are the sole managing members of both PH III GP and PH VII GP and may be deemed to have shared voting and dispositive power with respect to the shares of Common Stock held directly by PH III and PH VII. Clive Meanwell and Christopher Cox disclaim beneficial ownership of the shares held directly by PH III and PH VII, except to the extent of their pecuniary interests therein, if any. Clive Meanwell has filed a separate Form 3 in respect of the Issuer.
F3: On March 28, 2022, PH III, PH VII and Clive Meanwell ("PH") and (i) Mithril II LP ("Mithril"), (ii) M28 Capital Management LP (together with certain of its affiliates, "M28"), (iii) Polaris Venture Partners V, L.P. and certain affiliates (collectively, "Polaris") and (iv) Adimab, LLC, orally agreed to coordinate and cooperate in certain of their activities with regard to the Issuer, which agreement was subsequently memorialized, also on March 28, 2022, in an email circulated among representatives of such persons. That agreement provides that each such person will vote its shares of Common Stock in favor of the election of certain director nominees at the Issuer's 2022 annual meeting. By virtue of such agreement, the forgoing persons may be deemed to be part of a "group" (within the meaning of Section 13(d)(3) of the Exchange Act) comprised of such persons.
F4: The Reporting Persons expressly disclaim beneficial ownership over any Common Stock that they may be deemed to beneficially own solely by reason of the agreement reached among Population Health, Mithril, M28, Polaris and Adimab, LLC, and beneficial ownership of any securities of the Issuer other than those reported on this Form 3 in which they have a direct pecuniary interest. This filing shall not be deemed an admission that the Reporting Persons are 10% shareholders for purposes of Section 16 of the Exchange Act.
MEDICINES CO /DE
Report date March 04, 2019 · Filed March 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 57,987 |
Ending reported balance
After 2019-03-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-03-04 · Tax withholding · Disposed 1,202 · Balance 59,423 F1: Shares of common stock were withheld for payment of taxes in connection with the vesting of 2,847 shares of restricted stock from previously reported grant. Row 2 · 2019-03-04 · Tax withholding · Disposed 1,436 · Balance 57,987 F2: Shares of common stock were withheld for payment of taxes in connection with the vesting of 3,750 shares of restricted stock from previously reported grant. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 334,955 |
Reported balance
Holding disclosure · report date 2019-03-04 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 334,955 F3: The reporting person holds a power of attorney with respect to this account. Members of the reporting person's immediate family may be considered to have a pecuniary interest in this account. The reporting person disclaims beneficial ownership of the shares held by this account except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of common stock were withheld for payment of taxes in connection with the vesting of 2,847 shares of restricted stock from previously reported grant.
F2: Shares of common stock were withheld for payment of taxes in connection with the vesting of 3,750 shares of restricted stock from previously reported grant.
F3: The reporting person holds a power of attorney with respect to this account. Members of the reporting person's immediate family may be considered to have a pecuniary interest in this account. The reporting person disclaims beneficial ownership of the shares held by this account except to the extent of his pecuniary interest therein.
Population Health Investment Co., Inc.
Report date November 17, 2020 · Filed November 17, 2020
This filing explicitly reported no securities owned.
SCIENTIFIC INDUSTRIES INC
Report date July 01, 2024 · Filed August 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2034-07-01 | Direct | 329,209 |
Reported balance
After 2024-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-07-01 · Grant · Acquired 10,000 · Balance 329,209 |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2034-07-01 | Direct | 334,209 |
Reported balance
After 2024-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-07-01 · Grant · Acquired 5,000 · Balance 334,209 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
DATAWATCH CORP
Report date November 20, 2018 · Filed December 13, 2018
Section 16 reporting ended · disclosed 2018-12-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 310,570 |
Reported balance
After 2018-11-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-11-20 · Gift · Disposed 31,000 · Balance 310,570 F1: Reflects the pro rata distribution for no additional consideration from WC Capital, LLC, of which Mr. Cox is managing member, exempt pursuant to Rule 16a-13. |
| Common StockSEC Table I · non-derivative | Direct | 12,501 |
Reported balance
After 2018-12-13 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2018-12-13 · Other · Disposed 298,069 · Balance 12,501 F2: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 5, 2018, by and among Datawatch Corporation, a Delaware corporation (the "Company"), Altair Engineering Inc., a Delaware corporation (the "Altair"), and Dallas Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Altair (the "Purchaser"), and the terms of the Tender and Support Agreement, dated as of November 5, 2018, by and among Altair, Purchaser and each stockholder of the Company listed on Annex I of the Tender and Support Agreement, the reporting person disposed of these shares of the Company's Common Stock in the tender offer launched by Purchaser |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-13 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2018-12-13 · Disposition to issuer · Disposed 12,501 · Balance 0 F3: Pursuant to the terms of restricted stock unit ("RSU") grant agreements, the vesting of RSUs was accelerated in connection with the Merger and such RSUs became fully vested effective immediately prior to the effective time of the merger contemplated by the Merger Agreement (the "Merger"). Pursuant to the terms of the Merger Agreement, each such RSU was cancelled in the Merger and, in lieu of any issuance of shares in settlement of such RSU, converted into the right to receive a cash payment equal to $13.10 per share (without interest and less any applicable tax withholding). |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2018-12-13 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2018-12-13 · Other · Disposed 35,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, these shares of the Company's Common Stock were disposed of in the tender offer launched by Purchaser. F5: Mr. Cox's spouse is a trustee and a beneficiary of the trust that holds these securities. Mr. Cox is neither a trustee nor a beneficiary of the trust. Mr. Cox disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that Mr. Cox is the beneficial owner of the securities for purposes of Section 16 or for any other purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the pro rata distribution for no additional consideration from WC Capital, LLC, of which Mr. Cox is managing member, exempt pursuant to Rule 16a-13.
F2: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 5, 2018, by and among Datawatch Corporation, a Delaware corporation (the "Company"), Altair Engineering Inc., a Delaware corporation (the "Altair"), and Dallas Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Altair (the "Purchaser"), and the terms of the Tender and Support Agreement, dated as of November 5, 2018, by and among Altair, Purchaser and each stockholder of the Company listed on Annex I of the Tender and Support Agreement, the reporting person disposed of these shares of the Company's Common Stock in the tender offer launched by Purchaser
F3: Pursuant to the terms of restricted stock unit ("RSU") grant agreements, the vesting of RSUs was accelerated in connection with the Merger and such RSUs became fully vested effective immediately prior to the effective time of the merger contemplated by the Merger Agreement (the "Merger"). Pursuant to the terms of the Merger Agreement, each such RSU was cancelled in the Merger and, in lieu of any issuance of shares in settlement of such RSU, converted into the right to receive a cash payment equal to $13.10 per share (without interest and less any applicable tax withholding).
F4: Pursuant to the terms of the Merger Agreement, these shares of the Company's Common Stock were disposed of in the tender offer launched by Purchaser.
F5: Mr. Cox's spouse is a trustee and a beneficiary of the trust that holds these securities. Mr. Cox is neither a trustee nor a beneficiary of the trust. Mr. Cox disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that Mr. Cox is the beneficial owner of the securities for purposes of Section 16 or for any other purposes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2024 Filed Aug 2, 2024 21:19 UTC | SCIENTIFIC INDUSTRIES INC SCND · Entity 8003 | GrantOption to Purchase Common Stock · Derivative | 5,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001557341-24-000005 · primary_doc.xml · derivative · entry 2 Cox Christopher T · CIK 0001557341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 334,209 Underlying: Common stock · 5,000 shares Expires 2034-07-01 Read SEC document |
| July 01, 2024 Filed Aug 2, 2024 21:19 UTC | SCIENTIFIC INDUSTRIES INC SCND · Entity 8003 | GrantOption to Purchase Common stock · Derivative | 10,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001557341-24-000005 · primary_doc.xml · derivative · entry 1 Cox Christopher T · CIK 0001557341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 329,209 Underlying: Common Stock · 10,000 shares Expires 2034-07-01 Read SEC document |
| April 01, 2024 Filed Jun 28, 2024 21:22 UTC | SCIENTIFIC INDUSTRIES INC scnd · Entity 8003 | GrantOptions to Purchase Common Stock · Derivative | 17,964 | Not disclosed Strike: $2.50 | Not disclosed |
DisclosureSEC source: 0001557341-24-000004 · primary_doc.xml · derivative · entry 1 Cox Christopher T · CIK 0001557341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 319,209 Underlying: Common Stock · 17,964 shares Expires 2034-04-01 F1 · price: On April 1, 2024 the Reporting Person and the Issuer entered into an agreement to elect to be paid for Reporting Person's fees as a Board Director in stock options in lieu of cash compensation. These options vest in twelve (12) monthly installments commencing on April 1, 2024 through April 1, 2025. F1 · derivative.exercise_date: On April 1, 2024 the Reporting Person and the Issuer entered into an agreement to elect to be paid for Reporting Person's fees as a Board Director in stock options in lieu of cash compensation. These options vest in twelve (12) monthly installments commencing on April 1, 2024 through April 1, 2025. Read SEC document |
| December 19, 2023 Filed Jun 28, 2024 21:13 UTC | SCIENTIFIC INDUSTRIES INC scnd · Entity 8003 | PurchaseWarrants to Purchase Common Stock · Derivative | 79,245 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001557341-24-000003 · primary_doc.xml · derivative · entry 2 Cox Christopher T · CIK 0001557341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 301,245 Underlying: Common Stock · 79,245 shares Expires 2028-12-19 Read SEC document |
| December 19, 2023 Filed Jun 28, 2024 21:13 UTC | SCIENTIFIC INDUSTRIES INC scnd · Entity 8003 | PurchaseCommon Stock | 79,245 | $2.00 | $158,490.00 |
DisclosureSEC source: 0001557341-24-000003 · primary_doc.xml · nonDerivative · entry 1 Cox Christopher T · CIK 0001557341 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 301,245 Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 18:25 UTC | MEDICINES CO /DE MDCO · Entity 152552 | Tax withholdingCommon Stock | 1,436 | $25.53 | $36,661.08 |
DisclosureSEC source: 0001179110-19-003471 · edgar.xml · nonDerivative · entry 2 Cox Christopher T · CIK 0001557341 · EVP & Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,987 F2 · shares: Shares of common stock were withheld for payment of taxes in connection with the vesting of 3,750 shares of restricted stock from previously reported grant. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 18:25 UTC | MEDICINES CO /DE MDCO · Entity 152552 | Tax withholdingCommon Stock | 1,202 | $25.53 | $30,687.06 |
DisclosureSEC source: 0001179110-19-003471 · edgar.xml · nonDerivative · entry 1 Cox Christopher T · CIK 0001557341 · EVP & Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,423 F1 · shares: Shares of common stock were withheld for payment of taxes in connection with the vesting of 2,847 shares of restricted stock from previously reported grant. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 16:25 UTC | MEDICINES CO /DE MDCO · Entity 152552 | GrantCommon Stock | 317 | $20.97 | $6,647.49 |
DisclosureSEC source: 0001179110-19-003038 · edgar.xml · nonDerivative · entry 1 Cox Christopher T · CIK 0001557341 · EVP & Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,625 F1 · shares: Shares of common stock acquired pursuant to The Medicines Company Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period beginning September 1, 2018 and ending February 28, 2019. In accordance with the terms of the ESPP, these share were purchased based on 85% of the fair market value closing price of the issuer's common stock on February 28, 2019. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 07:22 UTC | MEDICINES CO /DE MDCO · Entity 152552 | PurchaseCommon Stock | 113,500 | $17.70 | $2,008,950.00 |
DisclosureSEC source: 0001179110-18-014209 · edgar.xml · nonDerivative · entry 1 Cox Christopher T · CIK 0001557341 · EVP & Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 334,955 F1 · price: Represents the weighted average purchase price of the shares purchased ranging from a low of $17.56 to a high of $17.89 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: The shares are held by a trust of which the reporting person is the trustee. The reporting person disclaims beneficial ownership of the shares held by this account except to the extent of his pecuniary interest therein Read SEC document |
| December 13, 2018 Filed Dec 13, 2018 17:15 UTC | DATAWATCH CORP DWCH · Entity 161801 | OtherCommon Stock | 35,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-18-064479 · tv508868_4.xml · nonDerivative · entry 4 Cox Christopher T · CIK 0001557341 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F4 · price: Pursuant to the terms of the Merger Agreement, these shares of the Company's Common Stock were disposed of in the tender offer launched by Purchaser. F5 · ownership.nature: Mr. Cox's spouse is a trustee and a beneficiary of the trust that holds these securities. Mr. Cox is neither a trustee nor a beneficiary of the trust. Mr. Cox disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that Mr. Cox is the beneficial owner of the securities for purposes of Section 16 or for any other purposes. Read SEC document |
| December 13, 2018 Filed Dec 13, 2018 17:15 UTC | DATAWATCH CORP DWCH · Entity 161801 | Disposition to issuerCommon Stock | 12,501 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-18-064479 · tv508868_4.xml · nonDerivative · entry 3 Cox Christopher T · CIK 0001557341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: Pursuant to the terms of restricted stock unit ("RSU") grant agreements, the vesting of RSUs was accelerated in connection with the Merger and such RSUs became fully vested effective immediately prior to the effective time of the merger contemplated by the Merger Agreement (the "Merger"). Pursuant to the terms of the Merger Agreement, each such RSU was cancelled in the Merger and, in lieu of any issuance of shares in settlement of such RSU, converted into the right to receive a cash payment equal to $13.10 per share (without interest and less any applicable tax withholding). Read SEC document |
| December 13, 2018 Filed Dec 13, 2018 17:15 UTC | DATAWATCH CORP DWCH · Entity 161801 | OtherCommon Stock | 298,069 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-18-064479 · tv508868_4.xml · nonDerivative · entry 2 Cox Christopher T · CIK 0001557341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,501 F2 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 5, 2018, by and among Datawatch Corporation, a Delaware corporation (the "Company"), Altair Engineering Inc., a Delaware corporation (the "Altair"), and Dallas Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Altair (the "Purchaser"), and the terms of the Tender and Support Agreement, dated as of November 5, 2018, by and among Altair, Purchaser and each stockholder of the Company listed on Annex I of the Tender and Support Agreement, the reporting person disposed of these shares of the Company's Common Stock in the tender offer launched by Purchaser Read SEC document |
| November 20, 2018 Filed Dec 13, 2018 17:15 UTC | DATAWATCH CORP DWCH · Entity 161801 | GiftCommon Stock | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-064479 · tv508868_4.xml · nonDerivative · entry 1 Cox Christopher T · CIK 0001557341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,570 F1 · balance_after: Reflects the pro rata distribution for no additional consideration from WC Capital, LLC, of which Mr. Cox is managing member, exempt pursuant to Rule 16a-13. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 07:55 UTC | MEDICINES CO /DE MDCO · Entity 152552 | PurchaseCommon Stock | 50,300 | $19.73 | $992,419.00 |
DisclosureSEC source: 0001179110-18-012983 · edgar.xml · nonDerivative · entry 1 Cox Christopher T · CIK 0001557341 · EVP & Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 221,455 F1 · ownership.nature: The shares are held by a trust of which the reporting person is the trustee. The reporting person disclaims beneficial ownership of the shares held by this account except to the extent of his pecuniary interest therein. Read SEC document |
| August 31, 2018 Filed Sep 5, 2018 18:41 UTC | MEDICINES CO /DE MDCO · Entity 152552 | GrantCommon Stock | 375 | $28.28 | $10,605.00 |
DisclosureSEC source: 0001182489-18-000383 · edgar.xml · nonDerivative · entry 1 Cox Christopher T · CIK 0001557341 · EVP & Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,308 F1 · shares: Shares of common stock acquired pursuant to The Medicines Company Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period beginning March 1, 2018 and ending August 31, 2018. In accordance with the terms of the ESPP, these share were purchased based on 85% of the fair market value closing price of the issuer's common stock on March 1, 2018. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 17:03 UTC | DATAWATCH CORP DWCH · Entity 161801 | GrantCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-021391 · tv491406_4.xml · nonDerivative · entry 1 Cox Christopher T · CIK 0001557341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,228 F1 · price: The securities awarded on 4/17/2018 are in the form of restricted stock units (RSUs) issued pursuant to the Datawatch Third Amended and Restated 2011 Equity Compensation and Incentive Plan. 2,333 RSUs will vest on 5/1/2019 and an additional 2,333 RSUs will vest on 5/1/2020, with the final 2,334 RSUs vesting on 5/1/2021. This vesting schedule is subject to acceleration in certain instances in connection with an acquisition or other change of control event. F1 · balance_after: The securities awarded on 4/17/2018 are in the form of restricted stock units (RSUs) issued pursuant to the Datawatch Third Amended and Restated 2011 Equity Compensation and Incentive Plan. 2,333 RSUs will vest on 5/1/2019 and an additional 2,333 RSUs will vest on 5/1/2020, with the final 2,334 RSUs vesting on 5/1/2021. This vesting schedule is subject to acceleration in certain instances in connection with an acquisition or other change of control event. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 18:03 UTC | MEDICINES CO /DE MDCO · Entity 152552 | Tax withholdingCommon Stock | 1,010 | $33.29 | $33,622.90 |
DisclosureSEC source: 0001179110-18-003531 · edgar.xml · nonDerivative · entry 1 Cox Christopher T · CIK 0001557341 · EVP & Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,933 F1 · shares: Shares of common stock were withheld for payment of taxes in connection with the vesting of 2,847 shares of restricted stock from previously reported grants. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 17:17 UTC | MEDICINES CO /DE MDCO · Entity 152552 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-003320 · edgar.xml · nonDerivative · entry 2 Cox Christopher T · CIK 0001557341 · EVP & Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,943 F2 · shares: Shares of restricted stock vest in 25% increments on each anniversary of the date of grant, until fully vested. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 17:17 UTC | MEDICINES CO /DE MDCO · Entity 152552 | GrantCommon Stock | 330 | $26.02 | $8,586.60 |
DisclosureSEC source: 0001179110-18-003320 · edgar.xml · nonDerivative · entry 1 Cox Christopher T · CIK 0001557341 · EVP & Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,943 F1 · shares: Acquired pursuant to The Medicines Company Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period beginning September 1, 2017 and ending February 28, 2018. In accordance with the terms of the ESPP, these shares were purchased based on 85% of the fair market value closing price of the issuer's common stock on February 28, 2018. Read SEC document |
| January 31, 2018 Filed Apr 5, 2018 16:30 UTC | DATAWATCH CORP DWCH · Entity 161801 | GiftCommon Stock | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-019402 · tv490393_4.xml · nonDerivative · entry 1 Cox Christopher T · CIK 0001557341 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 670,966 F1 · balance_after: Includes 670,966 shares held by WC Capital, LLC. Mr. Cox, as an investor in and Managing Member of WC Capital, LLC, shares the power to vote and dispose of all 670,966 shares of the Common Stock of the Company held by WC Capital, LLC. F1 · ownership.nature: Includes 670,966 shares held by WC Capital, LLC. Mr. Cox, as an investor in and Managing Member of WC Capital, LLC, shares the power to vote and dispose of all 670,966 shares of the Common Stock of the Company held by WC Capital, LLC. Read SEC document |
| January 31, 2018 Filed Jul 18, 2018 12:23 UTC | DATAWATCH CORP DWCH · Entity 161801 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-038808 · v498609_4.xml · nonDerivative · entry 1 Cox Christopher T · CIK 0001557341 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 665,966 F1 · balance_after: Includes 665,966 shares held by WC Capital, LLC. Mr. Cox, as an investor in and Managing Member of WC Capital, LLC, shares the power to vote and dispose of all 665,966 shares of the Common Stock of the Company held by WC Capital, LLC. F1 · ownership.nature: Includes 665,966 shares held by WC Capital, LLC. Mr. Cox, as an investor in and Managing Member of WC Capital, LLC, shares the power to vote and dispose of all 665,966 shares of the Common Stock of the Company held by WC Capital, LLC. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 17:29 UTC | MEDICINES CO /DE MDCO · Entity 152552 | GrantCommon Stock | 237 | $31.18 | $7,389.66 |
DisclosureSEC source: 0001179110-17-011996 · edgar.xml · nonDerivative · entry 1 Cox Christopher T · CIK 0001557341 · EVP & Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,613 F1 · shares: Acquired pursuant to The Medicines Company Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period beginning March 1, 2017 and ending August 31, 2017. In accordance with the terms of the ESPP, these shares were purchased based on 85% of the fair market value closing price of the issuer's common stock on August 31, 2017. Read SEC document |
| April 18, 2017 Filed Apr 20, 2017 16:35 UTC | DATAWATCH CORP DWCH · Entity 161801 | GrantCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-021276 · v464657_4.xml · nonDerivative · entry 1 Cox Christopher T · CIK 0001557341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,228 F1 · price: The securities awarded on 4/18/2017 are in the form of restricted stock units (RSUs) issued pursuant to the Datawatch Third Amended and Restated 2011 Equity Compensation and Incentive Plan. 2,333 RSUs will vest on 5/1/2018 and an additional 2,333 RSUs will vest on 5/1/2019, with the final 2,334 RSUs vesting on 5/1/2020. This vesting schedule is subject to acceleration in certain instances in connection with an acquisition or other change of control event. F1 · balance_after: The securities awarded on 4/18/2017 are in the form of restricted stock units (RSUs) issued pursuant to the Datawatch Third Amended and Restated 2011 Equity Compensation and Incentive Plan. 2,333 RSUs will vest on 5/1/2018 and an additional 2,333 RSUs will vest on 5/1/2019, with the final 2,334 RSUs vesting on 5/1/2020. This vesting schedule is subject to acceleration in certain instances in connection with an acquisition or other change of control event. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 19:07 UTC | MEDICINES CO /DE MDCO · Entity 152552 | GrantStock Option (right-to-buy) · Derivative | 70,265 | $0.00 Strike: $52.70 | $0.00 |
DisclosureSEC source: 0001179110-17-003720 · edgar.xml · derivative · entry 4 Cox Christopher T · CIK 0001557341 · EVP & Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,265 Underlying: Common Stock · 70,265 shares Expires 2027-03-01 F4 · derivative.exercise_date: The option vests in forty-eight equal installments beginning April 1, 2017. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 19:07 UTC | MEDICINES CO /DE MDCO · Entity 152552 | GrantCommon Stock | 11,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-003720 · edgar.xml · nonDerivative · entry 2 Cox Christopher T · CIK 0001557341 · EVP & Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,376 F2 · shares: Shares of restricted stock vest in 25% increments on each anniversary of the date of grant, until fully vested. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 19:07 UTC | MEDICINES CO /DE MDCO · Entity 152552 | GrantCommon Stock | 320 | $33.12 | $10,598.40 |
DisclosureSEC source: 0001179110-17-003720 · edgar.xml · nonDerivative · entry 1 Cox Christopher T · CIK 0001557341 · EVP & Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,990 F1 · shares: Shares of common stock acquired pursuant to The Medicines Company Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period beginning September 1, 2016 and ending February 28, 2017. In accordance with the terms of the ESPP, these shares were purchased based on 85% of the fair market value closing price of the issuer's common stock on September 1, 2016. Read SEC document |
| December 08, 2016 Filed Dec 9, 2016 11:37 UTC | MEDICINES CO /DE MDCO · Entity 152552 | PurchaseCommon Stock | 16,500 | $32.52 | $536,580.00 |
DisclosureSEC source: 0001179110-16-032655 · edgar.xml · nonDerivative · entry 2 Cox Christopher T · CIK 0001557341 · EVP & Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 171,155 F3 · price: Represents the weighted average purchase price of the shares purchased ranging from a low of $32.13 to a high of $32.87 per share. F2 · ownership.nature: The reporting person holds a power of attorney with respect to this account. Members of the reporting person's immediate family may be considered to have a pecuniary interest in this account. The reporting person disclaims beneficial ownership of the shares held by this account except to the extent of his pecuniary interest therein. Read SEC document |
| December 07, 2016 Filed Dec 9, 2016 11:37 UTC | MEDICINES CO /DE MDCO · Entity 152552 | PurchaseCommon Stock | 89,000 | $33.33 | $2,966,370.00 |
DisclosureSEC source: 0001179110-16-032655 · edgar.xml · nonDerivative · entry 1 Cox Christopher T · CIK 0001557341 · EVP & Chief Corp. Dev. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 154,655 F1 · price: Represents the weighted average purchase price of the shares purchased ranging from a low of $32.73 to a high of $33.49 per share. The reporting person undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price for this footnote (1) and footnote (3). F2 · ownership.nature: The reporting person holds a power of attorney with respect to this account. Members of the reporting person's immediate family may be considered to have a pecuniary interest in this account. The reporting person disclaims beneficial ownership of the shares held by this account except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.